Dear editor,Bispecific T-cell engagers(also referred to as BiTEs)are bi/multispecific antibodies that are a clinically used cancer immunotherapy,which enforce formation of an immunological synapse between T-cells and ...Dear editor,Bispecific T-cell engagers(also referred to as BiTEs)are bi/multispecific antibodies that are a clinically used cancer immunotherapy,which enforce formation of an immunological synapse between T-cells and tumour cells by antigenic engagement on the respective cells,resulting in cancer cell apoptosis.1,2 Tumour heterogeneity,however,is a major challenge for identifying the most appropriate cancer target antigen for each patient.Discovery of new tumour targets outweighs new BiTE approval,calling for rapid screening tools to evaluate novel targets and BiTE combinational formats.展开更多
基金supported by the Novo Nordisk Foundation Grant,CEMBID(Center for Multifunctional Biomolecular Drug Design,Grant Number:NNF17OC0028070)the National Key Research and Development Programme(2024 YFA0918600)+1 种基金Venus Project from China-Japan Union Hospital of Jilin University(Funding No.:XHQMX20242)the Science and Technology Development Plan Project of Jilin Province(Grant No.:20230402040GH).
文摘Dear editor,Bispecific T-cell engagers(also referred to as BiTEs)are bi/multispecific antibodies that are a clinically used cancer immunotherapy,which enforce formation of an immunological synapse between T-cells and tumour cells by antigenic engagement on the respective cells,resulting in cancer cell apoptosis.1,2 Tumour heterogeneity,however,is a major challenge for identifying the most appropriate cancer target antigen for each patient.Discovery of new tumour targets outweighs new BiTE approval,calling for rapid screening tools to evaluate novel targets and BiTE combinational formats.
